Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Humacyte Inc.

    NASDAQ: HUMA · Real-Time Price · USD
    2.41
    0.04 (1.69%)
    At close: Jun 16, 2025, 3:59 PM
    2.39
    -0.80%
    After-hours: Jun 16, 2025, 07:48 PM EDT
    1.69%
    Bid 2.39
    Market Cap 373.84M
    Revenue (ttm) 7.75M
    Net Income (ttm) -77.67M
    EPS (ttm) -0.69
    PE Ratio (ttm) -3.49
    Forward PE -8.48
    Analyst Buy
    Ask 2.48
    Volume 1,367,433
    Avg. Volume (20D) 4,940,119
    Open 2.44
    Previous Close 2.37
    Day's Range 2.37 - 2.46
    52-Week Range 1.15 - 9.79
    Beta 2.00

    About HUMA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol HUMA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for HUMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +31.06%
    Humacyte shares are trading higher after the compa... Unlock content with Pro Subscription
    2 months ago
    -30.56%
    Humacyte shares are trading lower after the company priced a $50 million public offering of 25 million common shares at $2.00 per share.
    news image

    5 days ago · seekingalpha.com

    Humacyte: Revenue Ramp From Symvess Incoming

    Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M ...

    news image

    2 weeks ago · zacks.com

    Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

    Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

    news image

    1 month ago · seekingalpha.com

    Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

    Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Fo...

    news image

    1 month ago · zacks.com

    Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

    Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.

    news image

    1 month ago · zacks.com

    Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

    The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.

    news image

    1 month ago · zacks.com

    All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy

    Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · zacks.com

    Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note

    Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.

    news image

    2 months ago · zacks.com

    Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know

    Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.

    news image

    2 months ago · seekingalpha.com

    Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

    Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason -...

    news image

    2 months ago · zacks.com

    Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

    The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy...

    Add to Watchlist